STAT

Coronavirus pandemic forces some research labs to shut down, with uncertain futures for scientific projects

As scientists who study coronaviruses are grinding away at their research, some of their counterparts in other academic laboratories are winding their work down, as the pandemic leads to institutional…

Scientists who study coronaviruses or design antiviral therapies are grinding away at their research like never before. But some of their counterparts in other academic laboratories are winding their work down, as the coronavirus pandemic leads to institutional shuttering and people avoiding working in close contact.

“Our goal is to minimize the number of people in our facilities at any one time, while allowing science that is absolutely essential to continue on-site,” Eric Lander, president of the Broad Institute of MIT and Harvard, wrote in an email to staff Saturday morning announcing that “non-critical” work at the institute had to wrap up by this coming Wednesday.

“We don’t know when these non-critical lab activities will resume, but we anticipate that the pause in lab activities will last at least a few weeks,”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related